Zasocitinib

Takeda's Phase 3 trial for oral psoriasis treatment zasocitinib has exceeded enrollment goals for underrepresented populations, completing recruitment six months ahead of schedule.

The JAK inhibitors therapeutic landscape shows robust growth with over 50 pharmaceutical companies developing 55+ pipeline candidates across various clinical stages.

Deucravacitinib demonstrates superior efficacy over apremilast in psoriasis treatment, with over 53% of patients achieving significant skin clearance at week 16.

Yale dermatology expert Dr. Christopher Bunick presents compelling data showing JAK inhibitors like upadacitinib and abrocitinib provide faster skin and itch relief compared to dupilumab in atopic dermatitis treatment.

Takeda's TAK-279, an oral TYK2 inhibitor, demonstrates significant skin clearance in Phase 2b trials for moderate to severe plaque psoriasis.